Iquest
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Iquest makes business-management software, tools that help small and medium-sized companies handle accounting, resource planning, and HR, delivered either as a cloud-based subscription service or as a fully installed system.
Its customers are businesses, primarily smaller Korean enterprises, that need structured back-office management. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company operates two divisions: a core software unit and an IT consulting subsidiary, Defocus, which handles system planning, implementation, and data analytics for corporate clients.
Summary is AI-generated and may contain errors · figures from DART filings
Its subsidiary Defocus handles the full IT consulting and system-integration work, giving the group an in-house delivery arm alongside its software products.
Iquest in five facts
What does Iquest do?
Iquest makes business-management software, tools that help small and medium-sized companies handle accounting, resource planning, and HR, delivered either as a cloud-based subscription service or as a fully installed system.
Where is Iquest listed and in which sector?
Iquest (Korean name: 아이퀘스트) trades under KRX code 262840 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Information Technology sector, Software.
How large is Iquest?
Its market capitalisation was US$22.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Iquest's latest annual revenue and operating profit?
For fiscal year 2025, Iquest reported revenue of US$32.9M, operating profit of US$3.2M and net income of US$4.5M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 7.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material event report (treasury share acquisition)
Iquest disclosed a plan to buy back its own shares worth US$740K, about 3.4% of its market value.
Treasury Shares · Sep 29 - Share cancellation decisionSep 9
- Trading suspension (share consolidation/split registration)M&A · Apr 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Iquest reported consolidated results for FY2025: revenue of US$30.3M (+7.2% year on year), operating profit of US$2.97M (+25.1% year on year) and net income of US$4.14M (+39.1% year on year).
Earnings · Feb 25 - Cash/in-kind dividend decision
Iquest declared a cash dividend of US$0.05 per share.
Dividend · Feb 25 - Treasury share disposal: results reportTreasury Shares · Jan 29
- Material event report (treasury share disposal)Treasury Shares · Jan 26